In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas

Journal of Antimicrobial Chemotherapy

Volumn 43, Issue 5, 1999, Pages 711-714

  Bébéar, Cécile M ^a   Renaudin, Hélène ^a   Schaeverbeke, Thierry ^a   Leblanc, Françoise ^b   Bébéar, Christiane ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b GlaxoWellcome   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DOXYCYCLINE; ERYTHROMYCIN; GREPAFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; MINIMUM INHIBITORY CONCENTRATION; MYCOPLASMA; NONHUMAN; UREAPLASMA;

EID: 0344673473     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/43.5.711     Document Type: Article

References (10)

1. Imada, T., Miyazaki, S., Nishida, M., Yamaguchi, K. & Goto, S. (1992). In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrobial Agents and Chemotherapy 36, 573-9.
2. Neu, H. C., Fang, W., Gu, J. W. & Chin, N. X. (1992). In vitro activity of OPC-17116. Antimicrobial Agents and Chemotherapy 36, 1310-5.
3. Ridgway, G. L., Salman, H., Robbins, M. J., Dencer, C. & Felmingham, D. (1997). The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 31-4.
4. Cook, P. J., Andrews, J. M., Wise, R., Honeybourne, D. & Moudgil, H. (1995). Concentrations of OPC-17116, a new fluoroquinolone antibacterial, in serum and lung compartments. Journal of Antimicrobial Chemotherapy 35, 317-26.
5. Bébéar, C. & Robertson J. (1996). Determination of minimal inhibitory concentration. In Molecular and Diagnostic Procedures in Mycoplasmology, Volume II, Diagnostic Procedures (Tully, J. G. &. Razin, S., Eds), pp. 189-99. Academic Press.
6. Bébéar, C. M., Renaudin, H., Boudjadja, A. & Bébéar, C. (1998). In vitro activity of BAY-128039, a new fluoroquinolone, against mycoplasmas. Antimicrobial Agents and Chemotherapy 42, 703-4.
7. Bébéar, C. M., Bové, J. M., Bébéar, C. & Renaudin, J. (1997). Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrobial Agents and Chemotherapy 41, 269-73.
8. Kenny, G. E. & Cartwright, F. D. (1993). Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116. Antimicrobial Agents and Chemotherapy 36, 1726-7.
9. Waites, K. B., Duffy, L. B., Schmid, T., Crabb, D., Pate, M. S. & Cassell, G. H. (1991). In vitro susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum, to sparfloxacin and PD 127391. Antimicrobial Agents and Chemotherapy 35, 1181-5.
10. Topkis, S., Swarz, H., Breisch, S. A. & Maroli, A. N. (1997). Efficacy and safety of grepafloxacin 600 mg daily for 10 days, in patients with community-acquired pneumonia. Clinical Therapeutics 19, 975-88.